NASDAQ:ACOR - Acorda Therapeutics Stock Price, Forecast & News

Acorda Therapeutics' stock was trading at $1.01 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ACOR shares have increased by 3.0% and is now trading at $1.04. View which stocks have been mosted impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acorda Therapeutics in the last year. There are currently 1 sell rating, 4 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Acorda Therapeutics.

Acorda Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, May 7th 2020. View our earnings forecast for Acorda Therapeutics.

Acorda Therapeutics Inc (NASDAQ:ACOR) released its earnings results on Thursday, February, 13th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.40) by $0.25. The biopharmaceutical company earned $50.50 million during the quarter, compared to analysts' expectations of $45.13 million. Acorda Therapeutics had a negative net margin of 141.87% and a negative return on equity of 22.18%. View Acorda Therapeutics' earnings history.

Acorda Therapeutics issued an update on its FY 2020 Pre-Market earnings guidance on Thursday, February, 13th. The company provided EPS guidance of for the period. The company issued revenue guidance of $130-160 million, compared to the consensus revenue estimate of $149.21 million.

6 brokerages have issued 1 year price objectives for Acorda Therapeutics' stock. Their forecasts range from $1.40 to $12.00. On average, they anticipate Acorda Therapeutics' share price to reach $7.23 in the next year. This suggests a possible upside of 595.5% from the stock's current price. View analysts' price targets for Acorda Therapeutics.

Headlines about ACOR stock have been trending very positive recently, InfoTrie reports. The research group identifies positive and negative press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Acorda Therapeutics earned a media sentiment score of 4.0 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news aboutAcorda Therapeutics.

Some companies that are related to Acorda Therapeutics include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Acorda Therapeutics investors own include InterDigital Wireless (IDCC), Nektar Therapeutics (NKTR), Applied Materials (AMAT), Gilead Sciences (GILD), Western Digital (WDC), Intel (INTC), Ionis Pharmaceuticals (IONS), Micron Technology (MU), FTS International (FTSI) and Advanced Micro Devices (AMD).

Acorda Therapeutics trades on the NASDAQ under the ticker symbol "ACOR."

Acorda Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Point72 Asset Management L.P. (9.76%), Renaissance Technologies LLC (8.03%), Partner Fund Management L.P. (3.94%), Acadian Asset Management LLC (3.88%), State Street Corp (3.06%) and AQR Capital Management LLC (2.85%). Company insiders that own Acorda Therapeutics stock include Andrew A Hindman, Burkhard Blank, David Lawrence, Ian F Smith, Jane Wasman, Lauren M Sabella, Lorin Randall, Ron Cohen, Scopia Capital Management Lp and Steven M Rauscher. View institutional ownership trends for Acorda Therapeutics.

ACOR stock was sold by a variety of institutional investors in the last quarter, including Partner Fund Management L.P., Jefferies Group LLC, Geode Capital Management LLC, Partner Investment Management L.P., Bank of New York Mellon Corp, Diamond Hill Capital Management Inc., Renaissance Technologies LLC, and Prudential Financial Inc.. Company insiders that have sold Acorda Therapeutics company stock in the last year include Jane Wasman, and Ron Cohen. View insider buying and selling activity for Acorda Therapeutics.

ACOR stock was bought by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., AQR Capital Management LLC, Skandinaviska Enskilda Banken AB publ, Acadian Asset Management LLC, Norges Bank, Jacobs Levy Equity Management Inc., Strs Ohio, and Bank of America Corp DE. View insider buying and selling activity for Acorda Therapeutics.

Shares of ACOR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ACOR stock can currently be purchased for approximately $1.04.

Acorda Therapeutics has a market capitalization of $49.92 million and generates $192.41 million in revenue each year. The biopharmaceutical company earns $-272,970,000.00 in net income (profit) each year or ($1.99) on an earnings per share basis. Acorda Therapeutics employs 474 workers across the globe. View additional information about Acorda Therapeutics.

The official website for Acorda Therapeutics is http://www.acorda.com/.

Acorda Therapeutics' mailing address is 420 SAW MILL RIVER ROAD, ARDSLEY NY, 10502. The biopharmaceutical company can be reached via phone at 914-347-4300.